Central nervous targets for the treatment of bladder dysfunction

Neurourology and Urodynamics

Volumn 33, Issue 1, 2014, Pages 59-66

  Yoshimura, Naoki ^a   Miyazato, Minoru ^a   Kitta, Takeya ^a   Yoshikawa, Satoru ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

adenosine; bladder overactivity; central nervous system; GABA; gene therapy; glycine

Indexed keywords

17 METHYLNALOXONE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 AMINOBUTYRIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALX 1393; BACLOFEN; BOTULINUM TOXIN A; BROMOCRIPTINE; CAPSAICIN; DOPAMINE; ENDOTHELIN A RECEPTOR; GANAXOLONE; GLUTAMATE DECARBOXYLASE; GLYCINE; LEVODOPA; NALOXONE; NEUROKININ; NEUROPEPTIDE; NEUROTRANSMITTER; NITRIC OXIDE; NORADRENALIN; PERGOLIDE; PURINERGIC P2X3 RECEPTOR; QUINPIROLE; RESINIFERATOXIN; SARCOSINE; SEROTONIN; STRYCHNINE; TACHYKININ; TRAMADOL; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER DYSFUNCTION; BLADDER FUNCTION; BLADDER IRRITATION; CENTRAL NERVOUS SYSTEM; CYSTOMETRY; DESENSITIZATION; EPILEPSY; EXOCYTOSIS; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; IDIOPATHIC DISEASE; MICTURITION DISORDER; MICTURITION REFLEX; NERVE CELL DEGENERATION; NERVOUS SYSTEM INJURY; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PREGANGLIONIC NERVE CELL; PROTEIN EXPRESSION; SACRAL SPINAL CORD; SENSORY NERVE; SPASTICITY; SPINAL CORD INJURY; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPTOSOME; UNSPECIFIED SIDE EFFECT; URETHRA; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VENTRAL TEGMENTUM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOSINE; BLADDER OVERACTIVITY; CENTRAL NERVOUS SYSTEM; GABA; GENE THERAPY; GLYCINE;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION; URODYNAMICS; UROLOGICAL AGENTS;

EID: 84890316933     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22455     Document Type: Article

References (100)

1. Fowler CJ, Griffiths D, de Groat WC,. The neural control of micturition. Nat Rev Neurosci 2008; 9: 453-66.
2. Fry C, Brading AF, Hussain M,. Cell biology. In:, Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Plymouth UK: Health Publication Ltd; 2005. 313-62.
3. Yoshimura N, Chancellor MB,. Physiology and pharmacology of the bladder and urethra. In:, Wein AJ, Kavoussi LR, Novick AC, et al., editors. Campbell-Walsh urology, 10th edition. New York: Saunders; 2011. 1786-833.
4. Morrison J, Birder L, Craggs M,. Neural control. In:, Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Plymouth UK: Health Publication Ltd; 2005. 363-422.
5. Mayer ML, Westbrook GL,. The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 1987; 28: 197-276.
6. Igawa Y, Mattiasson A, Andersson KE,. Effects of GABA-receptor stimulation and blockade on micturition in normal rats and rats with bladder outflow obstruction. J Urol 1993; 150: 537-42.
7. Miyazato M, Sugaya K, Nishijima S, et al. Inhibitory effect of intrathecal glycine on the micturition reflex in normal and spinal cord injury rats. Exp Neurol 2003; 183: 232-40.
8. Araki I,. Inhibitory postsynaptic currents and the effects of GABA on visually identified sacral parasympathetic preganglionic neurons in neonatal rats. J Neurophysiol 1994; 72: 2903-10.
9. Bushman W, Steers WD, Meythaler JM,. Voiding dysfunction in patients with spastic paraplegia: Urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 1993; 12: 163-70.
10. Giuliani S, Lecci A, Santicioli P, et al. Effect of the GABAB antagonist, phaclofen, on baclofen-induced inhibition of micturition reflex in urethane-anesthetized rats. Neuroscience 1992; 48: 217-23.
11. Miyazato M, Sugaya K, Nishijima S, et al. Dietary glycine inhibits bladder activity in normal rats and rats with spinal cord injury. J Urol 2005; 173: 314-17.
12. Miyazato M, Sasatomi K, Hiragata S, et al. GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord injured rats. J Urol 2008; 179: 1178-83.
13. Miyazato M, Sasatomi K, Hiragata S, et al. Suppression of detrusor-sphincter dyssynergia by GABA-receptor activation in the lumbosacral spinal cord in spinal cord-injured rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R336-42.
14. Stephen LJ, Brodie MJ,. Pharmacotherapy of epilepsy: Newly approved and developmental agents. CNS Drugs 2011; 25: 89-107.
15. Richard I, Menei P,. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir Suppl 2007; 97: 213-8.
16. de Groat WC, Roppolo JR, Yoshimura N, et al. Neural control of the urinary bladder and colon In:, Taché Y, Wingate D, Burks T, editors. Boca Raton, FL: CRC Press; 1993. 167-90.
17. de Groat WC, Yoshimura N,. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001; 41: 691-721.
18. Yoshimura N, de Groat WC,. Neural control of the lower urinary tract. Int J Urol 1997; 4: 111-25.
19. Dray A, Metsch R,. Inhibition of urinary bladder contractions by a spinal action of morphine and other opioids. J Pharmacol Exp Ther 1984; 231: 254-60.
20. Dray A, Metsch R,. Opioid receptor subtypes involved in the central inhibition of urinary bladder motility. Eur J Pharmacol 1984; 104: 47-53.
21. Dray A, Metsch R,. Opioids and central inhibition of urinary bladder motility. Eur J Pharmacol 1984; 98: 155-6.
22. Kamo I, Chancellor MB, de Groat WC, et al. Differential effects of activation of peripheral and spinal tachykinin neurokinin (3) receptors on the micturition reflex in rats. J Urol 2005; 174: 776-81.
23. Ogawa T, Kamo I, Pflug BR, et al. Differential roles of peripheral and spinal endothelin receptors in the micturition reflex in rats. J Urol 2004; 172: 1533-37.
24. Andersson KE,. Pharmacotherapy of the overactive bladder. Discov Med 2009; 8: 118-24.
25. Ouslander JG,. Management of overactive bladder. N Engl J Med 2004; 350: 786-99.
26. Geirsson G, Lindstrom S, Fall M,. The bladder cooling reflex and the use of cooling as stimulus to the lower urinary tract. J Urol 1999; 162: 1890-6.
27. Chai TC, Gray ML, Steers WD,. The incidence of a positive ice water test in bladder outlet obstructed patients: Evidence for bladder neural plasticity. J Urol 1998; 160: 34-8.
28. Hirayama A, Fujimoto K, Matsumoto Y, et al. Positive response to ice water test associated with high-grade bladder outlet obstruction in patients with benign prostatic hyperplasia. Urology 2003; 62: 909-13.
29. Hirayama A, Fujimoto K, Matsumoto Y, et al. Nocturia in men with lower urinary tract symptoms is associated with both nocturnal polyuria and detrusor overactivity with positive response to ice water test. Urology 2005; 65: 1064-9.
30. Chancellor MB, Fowler CJ, Apostolidis A, et al. Drug Insight: Biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008; 5: 319-28.
31. Apostolidis A, Dasgupta P, Fowler CJ,. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50.
32. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-82; discussion 982-73.
33. Yoshimura N, Chancellor MB,. Current and future pharmacological treatment for overactive bladder. J Urol 2002; 168: 1897-913.
34. Takahashi R, Yunoki T, Naito S, et al. Differential effects of botulinum neurotoxin a on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats. J Urol 2012; 188: 1993-9.
35. Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol 2004; 46: 247-53.
36. Silva C, Ribeiro MJ, Cruz F,. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002; 168: 575-9.
37. Birder L, de Groat W, Mills I, et al. Neural control of the lower urinary tract: Peripheral and spinal mechanisms. Neurourol Urodyn 2010; 29: 128-39.
38. Yoshimura N, Birder L,. Interstitial: cystitis and related painful bladder syndromes: Pathophysiology. In:, Pasricha PJ, Willis WD, Gebhart GF, editors. Chronic abdominal and visceral pain: Theory and practice. New York: Informa Healthcare; 2007. 495-520.
39. Yoshimura N, Kaiho Y, Miyazato M, et al. Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 437-48.
40. Shapiro S,. Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma-aminobutyric acid in the normal and injured spinal cord. Neurosurgery 1997; 40: 168-76; discussion 177.
41. Liu J, Wolfe D, Hao S, et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004; 10: 57-66.
42. Hao S, Mata M, Wolfe D, et al. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 2005; 57: 914-8.
43. Steers WD, Meythaler JM, Haworth C, et al. Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology. J Urol 1992; 148: 1849-55.
44. Miyazato M, Sugaya K, Goins WF, et al. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther 2009; 16: 660-8.
45. de Groat WC, Yoshimura N,. Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res 2006; 152: 59-84.
46. Cheng C-L, Ma C-P, de Groat WC,. Effect of capsaicin on micturition and associated reflexes in chronic spinal rats. Brain Res 1995; 678: 40-8.
47. Miyazato M, Sugaya K, Saito S, et al. Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats. J Urol 2010; 184: 1204-10.
48. Glazer EJ, Basbaum AI,. Leucine enkephalin: Localization in and axoplasmic transport by sacral parasympathetic preganglionic neurons in the cat. Science 1980; 208: 1479-81.
49. Dray A, Nunan L, Wire W,. Central delta-opioid receptor interactions and the inhibition of reflex urinary bladder contractions in the rat. Br J Pharmacol 1985; 85: 717-26.
50. Goins WF, Goss JR, Chancellor MB, et al. Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther 2009; 16: 558-69.
51. Yokoyama H, Sasaki K, Franks ME, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkepahlin. Hum Gene Ther 2009; 20: 63-71.
52. Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: Results of a phase I clinical trial. Ann Neurol 2011; 70: 207-12.
53. Wolfe D, Mata M, Fink DJ,. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 2009; 16: 455-60.
54. Wolfe D, Wechuck J, Krisky D, et al. A clinical trial of gene therapy for chronic pain. Pain Med 2009; 10: 1325-30.
55. Zeilhofer HU,. The glycinergic control of spinal pain processing. Cell Mol Life Sci 2005; 62: 2027-35.
56. Miyazato M, Sugaya K, Nishijima S, et al. Intrathecal or dietary glycine inhibits bladder and urethral activity in rats with spinal cord injury. J Urol 2005; 174: 2397-400.
57. Miyazato M, Sugaya K, Nishijima S, et al. Changes of bladder activity and glycine levels in the lumbosacral cord after partial bladder outlet obstruction in rats. Int J Urol 2008; 15: 843-7.
58. Nishijima S, Sugaya K, Fukuda T, et al. Serum amino acids as indicators of cerebrospinal neuronal activity in patients with micturition disorders. Int J Urol 2006; 13: 1479-83.
59. Zafra F, Aragon C, Olivares L, et al. Glycine transporters are differentially expressed among CNS cells. J Neurosci 1995; 15: 3952-69.
60. Zafra F, Gomeza J, Olivares L, et al. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 1995; 7: 1342-52.
61. Eulenburg V, Armsen W, Betz H, et al. Glycine transporters: Essential regulators of neurotransmission. Trends Biochem Sci 2005; 30: 325-33.
62. Boulay D, Pichat P, Dargazanli G, et al. Characterization of SSR, 103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 2008; 91: 47-58.
63. Mohler H, Boison D, Singer P, et al. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: Evidence from genetically modified mouse models and pharmacological inhibition. Biochem Pharmacol 2011; 81: 1065-77.
64. Manahan-Vaughan D, Wildforster V, Thomsen C,. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci 2008; 28: 1342-50.
65. Dohi T, Morita K, Kitayama T, et al. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther 2009; 123: 54-79.
66. Haranishi Y, Hara K, Terada T, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg 2010; 110: 615-21.
67. Yoshikawa S, Oguchi T, Funahashi Y, et al. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur Urol 62: 704-12.
68. Albanese A, Jenner P, Marsden CD, et al. Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci Lett 1988; 87: 46-50.
69. Hashimoto K, Oyama T, Sugiyama T, et al. Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D1 and D2 receptors in rats. J Pharmacol Sci 2003; 92: 143-8.
70. Kontani H, Inoue T, Sakai T,. Dopamine receptor subtypes that induce hyperactive urinary bladder response in anesthetized rats. Jpn J Pharmacol 1990; 54: 482-6.
71. Seki S, Igawa Y, Kaidoh K, et al. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001; 20: 105-13.
72. Yokoyama O, Yoshiyama M, Namiki M, et al. Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol 1999; 276: R935-42.
73. Yoshimura N, Kuno S, Chancellor MB, et al. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol 2003; 139: 1425-32.
74. Yoshimura N, Mizuta E, Kuno S, et al. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 1993; 32: 315-21.
75. Yoshimura N, Mizuta E, Yoshida O, et al. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 1998; 286: 228-33.
76. Yoshimura N, Sasa M, Yoshida O, et al. Dopamine D-1 receptor mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn 1992; 11: 535-45.
77. Sakakibara R, Nakazawa K, Shiba K, et al. Firing patterns of micturition-related neurons in the pontine storage centre in cats. Auton Neurosci 2002; 99: 24-30.
78. Yamamoto T, Sakakibara R, Hashimoto K, et al. Striatal dopamine level increases in the urinary storage phase in cats: An in vivo microdialysis study. Neuroscience 2005; 135: 299-303.
79. Ogawa T, Seki S, Masuda H, et al. Dopaminergic mechanisms controlling urethral function in rats. Neurourol Urodyn 2006; 25: 480-9.
80. Araki I, Kitahara M, Oida T, et al. Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms. J Urol 2000; 164: 1640-3.
81. Araki I, Kuno S,. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000; 68: 429-33.
82. Berger Y, Blaivas JG, DeLaRocha ER, et al. Urodynamic findings in Parkinson's disease. J Urol 1987; 138: 836-8.
83. Bonnet AM, Pichon J, Vidailhet M, et al. Urinary disturbances in striatonigral degeneration and Parkinson's disease: Clinical and urodynamic aspects. Mov Disord 1997; 12: 509-13.
84. Pavlakis AJ, Siroky MB, Goldstein I, et al. Neurourologic findings in Parkinson's disease. J Urol 1983; 129: 80-3.
85. Aranda B, Cramer P,. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 1993; 12: 203-9.
86. Sakakibara R, Hattori T, Uchiyama T, et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001; 71: 600-6.
87. Sakakibara R, Tateno F, Kishi M, et al. Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol Dis 2012; 46: 565-71.
88. Sakakibara R, Shinotoh H, Uchiyama T, et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 2001; 187: 55-9.
89. Winge K, Fowler CJ,. Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21: 737-45.
90. Winge K, Friberg L, Werdelin L, et al. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005; 12: 842-50.
91. Matsuura S, Kakizaki H, Mitsui T, et al. Human brain region response to distention or cold stimulation of the bladder: A positron emission tomography study. J Urol 2002; 168: 2035-9.
92. Kitta T, Kakizaki H, Furuno T, et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: A positron emission tomography study. J Urol 2006; 175: 994-8.
93. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997; 20: 523-30.
94. Olanow CW, Obeso JA,. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors. Neurology 2000; 55: S72-7; discussion S78-81.
95. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa 056 study group. N Engl J Med 2000; 342: 1484-91.
96. Brusa L, Petta F, Pisani A, et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease. J Urol 2006; 175: 202-6; discussion 206-7.
97. Uchiyama T, Sakakibara R, Hattori T, et al. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003; 18: 573-8.
98. Pinna A, Wardas J, Simola N, et al. New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists. Life Sci 2005; 77: 3259-67.
99. Schwarzschild MA, Agnati L, Fuxe K, et al. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006; 29: 647-54.
100. Kitta T, Chancellor MB, de Groat WC, et al. Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease. J Urol 2012; 187: 1890-7.